Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2002

View Archived Issues

Viventia options anticancer hybridomas from M.D. Cancer Center

VaxGen awarded government contract for anthrax vaccine

Clinical section of Vitrase NDA submitted

DAC:GLP-1 phase I results delayed

Cortex and Servier expand Ampakine research collaboration

IL-21 added to ZymoGenetics development pipeline

Safety and pharmacokinetics of LY-451395 in healthy volunteers

Glutamate mglu5-selective antagonist may potentiate activity of conventional AEDs

Pimecrolimus a highlight of this year's EADV congress

Antiepileptic drugs in bipolar disorder

Olanzapine/fluoxetine combination in major depression

Two series of PPARalpha and/or PPARgamma agonists identified at Dr. Reddy's

Inhibitors of TGF-beta signaling pathway described in GSK patent

Pharmacia evaluating inhibitors of viral DNA polymerase

Novel GlyT-2 inhibitors and their use in psychosis, pain, epilepsy, etc.

Potential antidiabetic thiazolidinones prepared and tested at Merck

Merck patent covers novel alpha1A-adrenoceptor antagonists and their use in BPH

Novel beta3-adrenoceptor agonists under study at BMS

VRC-3375 used as a lead to develop more potent antibacterial PDF inhibitors

Neuropharmacological profile of SLV-313, a dual D2 antagonist/5-HT1A agonist

Korean research demonstrates stimulation of hair growth following culture with epigallocatechin

Timing of single doses of FK-506 important for limb allograft success

Thrombin-related peptide accelerates fracture healing in first human trial

Karo Bio and Bristol-Myers Squibb extend obesity collaboration

Initiation of phase II Triapine trial in head and neck cancer

Enrollment completed in phase II Theratope trial for metastatic colorectal cancer

Fuzeon, the first HIV fusion inhibitor, will receive a priority review at the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.